Biosimilars approved in Japan / General / Biosimilars / Home - GaBi Online

Biosimilars approved in Japan

Biosimilars/General | Posted 07/03/2014 0 Post your comment

Last update: 24 October 2023

In Japan, the regulatory body for the approval of medicines, including biologicals, is the Ministry for Health Labour and Welfare (MHLW).

The Pharmaceuticals and Medical Devices Agency (PMDA) is a Japanese regulatory agency, working together with MHLW. PMDA’s Office of Biologicals provides consultations concerning the clinical trials of new drugs and medical devices and handles biotechnology medicines, including biosimilars.

In March 2009, guidelines for biosimilars, based on the European Union’s existing processes, were published by the MHLW [1].

These guidelines consider biosimilar drugs to be those products that are equivalent and homogenous to the reference biological product in terms of efficacy, quality and safety.

The first biosimilar to receive approval in Japan was Sandoz’s growth hormone treatment Somatropin BS (somatropin) in June 2009. To date, the PMDA has approved 35 biosimilars, within the product classes of human growth hormone, granulocyte colony-stimulating factor, erythropoiesis stimulating agent, insulin, angiogenesis inhibitor and tumour necrosis factor (TNF)-inhibitor, for use in Japan, see Table 1.

Table 1: PMDA approved biosimilars*
Product name [JAN]	Active substance	Therapeutic area**	Authorization date	Manufacturer/ Company name
Adalimumab BS [adalimumab biosimilar 1]	adalimumab	Ankylosing spondylitis Crohn’s disease Entero-Behcet's Disease Juvenile idiopathic arthritis Psoriatic arthritis Psoriasis Rheumatoid arthritis Psoriasis	29 Jun 2020	Fujifilm Kyowa Kirin Biologics
Adalimumab BS [adalimumab biosimilar 2]		Ankylosing spondylitis Crohn’s disease Entero-Behcet's Disease Juvenile idiopathic arthritis Psoriatic arthritis Psoriasis Rheumatoid arthritis Psoriasis	22 Jan 2021	Daiichi Sankyo
Adalimumab BS MA [adalimumab biosimilar 3]	adalimumab	Ankylosing spondylitis Crohn’s disease Entero-Behcet's Disease Juvenile idiopathic arthritis Psoriatic arthritis Psoriasis Rheumatoid arthritis Psoriasis	23 Mar 2021	LG Chem/ Mochida Pharmaceutical
Agalsidase Beta BS [JCR] [agalsidase beta biosimilar 1]	agalsidase beta	Fabry disease	28 Nov 2018	JCR Pharmaceuticals
Bevacizumab BS [bevacizumab biosimilar 1]	bevacizumab	Colorectal cancer	18 Jun 2019	Pfizer Japan
Bevacizumab BS [bevacizumab biosimilar 2]	bevacizumab	Colorectal cancer	20 Sep 2019	Daiichi Sankyo
Bevacizumab BS [bevacizumab biosimilar 3]	bevacizumab	Metastatic colorectal cancer	27 Sep 2022	Celltrion
Darbepoetin alfa [KKF]	darbepoetin alfa	Anaemia	15 Aug 2018	Kyowa Hakko Kirin
Darbepoetin alfa (CKD‑11101)	darbepoetin alfa	Anaemia	4 Dec 2018	Chong Kun Dang Pharmaceutical
Darbepoetin alfa BS [darbepoetin alfa biosimilar 1]	darbepoetin alfa	Anaemia	20 Sep 2020	JCR Pharmaceuticals
Darbepoetin alfa BS [darbepoetin alfa biosimilar 2]	darbepoetin alfa	Anaemia	20 Sep 2020	Sanwa Kagaku Kenkyusyo
Darbepoetin alfa BS [darbepoetin alfa biosimilar 3]	darbepoetin alfa	Anaemia	20 Sep 2019	Mylan
Epoetin alfa BS [epoetin alfa biosimilar 1]	epoetin alfa	Anaemia Renal anaemia	20 Jan 2010	JCR Pharmaceuticals
Etanercept BS [etanercept biosimilar 1]	etanercept	Juvenile idiopathic arthritis Rheumatoid arthritis	19 Jan 2018	Mochida Pharmaceutical
Etanercept (YLB113) [etanercept biosimilar 2]	etanercept	Juvenile idiopathic arthritis Rheumatoid arthritis	26 Mar 2019	Kyowa Pharmaceutical Industry [YL Biologics (Lupin/ Yoshindo)]
Filgrastim BS [filgrastim biosimilar 1]	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	21 Nov 2012	Fuji Pharma/ Mochida Pharmaceutical
Filgrastim BS [filgrastim biosimilar 2]	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	28 Feb 2013	Teva Pharma Japan/Nippon Kayaku
Filgrastim BS [filgrastim biosimilar 3]	filgrastim	Cancer Haematopoietic stem cell transplantation Neutropenia	24 Mar 2014	Sandoz
Herzuma	trastuzumab	Gastric cancer	1 Mar 2018	Celltrion/Nippon Kayaku
Infliximab BS (Remsima) [infliximab biosimilar 1]	infliximab	Crohn’s disease Rheumatoid arthritis Ulcerative colitis	4 Jul 2014	Celltrion/Nippon Kayaku
Infliximab BS (Remsima) [infliximab biosimilar 2]	infliximab	Crohn’s disease Rheumatoid arthritis Psoriasis Ulcerative colitis	27 Sep 2017	Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical [2]
Infliximab BS (Remsima) [infliximab biosimilar 3]	infliximab	Crohn’s disease Rheumatoid arthritis Psoriasis Ulcerative colitis	2 Jul 2018	Pfizer Japan [3]
Insulin aspart BS [insulin aspart biosimilar 1]	insulin aspart	Diabetes	23 Mar 2021	Sanofi
Insulin glargine BS [insulin glargine biosimilar 1]	insulin glargine	Diabetes	26 Dec 2014	Eli Lilly/ Boehringer Ingelheim [4]
Insulin glargine BS [insulin glargine biosimilar 2]	insulin glargine	Diabetes	28 Mar 2016	Biocon/Fujifilm Pharma [5]
Insulin lispro BS [insulin lispro biosimilar 1]	insulin lispro	Diabetes	25 Mar 2020	Sanofi
Ranibizumab BS [ranibizumab biosimilar 1]	ranibizumab	Age-related macular degeneration	27 Sep 2021	Senju Pharmaceutical
Rituximab BS [rituximab biosimilar 1]	rituximab	B-cell non-Hodgkin’s lymphoma B-cell lymphoproliferative disorder Microscopic polyangiitis Wegener's granulomatosis	27 Sep 2017	Sandoz
Rituximab BS [rituximab biosimilar 2]	rituximab	B-cell non-Hodgkin’s lymphoma B-cell lymphoproliferative disorder Microscopic polyangiitis Wegener's granulomatosis	20 Sep 2020	Pfizer Japan
Somatropin BS	somatropin	Growth hormone deficiency Turner syndrome	22 Jun 2009	Sandoz
Teriparatide BS [teriparatide biosimilar 1]	teriparatide	Osteoporosis	20 Sep 2019	Mochida Pharmaceutical
Trastuzumab BS [trastuzumab biosimilar 1]	trastuzumab	HER2+ gastric cancer	23 Mar 2018	Celltrion
Trastuzumab BS [trastuzumab biosimilar 2]	trastuzumab	HER2+ gastric cancer	21 Sep 2018	Daiichi Sankyo
Trastuzumab BS [trastuzumab biosimilar 3]	trastuzumab	HER2+ gastric cancer	21 Sep 2018	Pfizer Japan
Ustekinumab BS [ustekinumab biosimilar 1]	ustekinumab	plaque psoriasis psoriatic arthritis	Sep 2023	Alovotech/Fuji Pharma
Data collected on 28 January 2014, updated on 24 October 2023. *Therapeutic area taken from company information, from originator product information on EMA website or from PMDA information [ ] = Japanese Approved Name (JAN).

Related articles
Japan approves second biosimilar G-CSF

Sandoz applies for Japanese approval for biosimilar G-CSF

Biosimilars approved in Europe

References
1. GaBI Online - Generics and Biosimilars Initiative. Japanese guidelines for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Aug 1]. Available from: www.gabionline.net/Guidelines/Japanese-guidelines-for-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Nichi-Iko gains Japanese approval for infliximab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jan 5]. Available from: www.gabionline.net/Biosimilars/News/Nichi-Iko-gains-Japanese-approval-for-infliximab-biosimilar
3. GaBI Online - Generics and Biosimilars Initiative. Pfizer gains Japanese approval for infliximab biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Aug 24]. Available from: www.gabionline.net/Biosimilars/News/Pfizer-gains-Japanese-approval-for-infliximab-biosimilar
4. GaBI Online - Generics and Biosimilars Initiative. Japanese approval for insulin glargine biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Feb 6]. Available from: www.gabionline.net/Biosimilars/News/Japanese-approval-for-insulin-glargine-biosimilar
5. GaBI Online - Generics and Biosimilars Initiative. Biocon receives Japanese approval for insulin glargine biosimilar [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 Apr 22]. Available from: www.gabionline.net/Biosimilars/News/Biocon-receives-Japanese-approval-for-insulin-glargine-biosimilar

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: PMDA